Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant
- PMID: 21735053
- DOI: 10.1007/s00431-011-1521-7
Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant
Abstract
Intrauterine transfusion is the standard of care in the management of severe Rh isoimmunization. Desferrioxamine has been used for the treatment of iron overload secondary to hemolysis and intrauterine transfusions in Rh isoimmunization cases. Here, we report a preterm infant born at 34 weeks of gestational age who had formerly received intrauterine transfusions for Rhesus hemolytic disease and presented with severe hyperferritinemia and elevated liver enzymes in the first week of life. Desferrioxamine treatment was started due to a ferritin level of 28,800 ng/ml and continued for 13 weeks. Although the treatment was successful, we observed resistant leukopenia which resolved after the cessation of treatment. In conclusion, iron overload secondary to intrauterine transfusions can be treated successfully with desferrioxamine; however, neonatologists must be aware of the possible side effects of this drug which has been used in only a limited number of newborns.
Similar articles
-
Chelation therapy for secondary neonatal iron over load: Lessons learned from rhesus hemolytic disease.Turk J Pediatr. 2018;60(3):335-339. doi: 10.24953/turkjped.2018.03.018. Turk J Pediatr. 2018. PMID: 30511551
-
Iron Overload and Anemia in Rhesus Hemolytic Disease of Newborn: A Prospective Observational Study.Indian J Pediatr. 2024 Aug;91(8):848-850. doi: 10.1007/s12098-023-04962-6. Epub 2023 Nov 27. Indian J Pediatr. 2024. PMID: 38010557
-
Introduction of a programme for intravascular transfusions at severe rhesus isoimmunization.J Perinat Med. 1988;16(5-6):417-22. doi: 10.1515/jpme.1988.16.5-6.417. J Perinat Med. 1988. PMID: 3149303
-
Rhesus disease: postnatal management and outcome.Eur J Pediatr. 1999 Sep;158(9):689-93. doi: 10.1007/s004310051180. Eur J Pediatr. 1999. PMID: 10485296 Review.
-
Rescue in inner space: management of Rh hemolytic disease.J Pediatr. 1997 Sep;131(3):340-2. doi: 10.1016/s0022-3476(97)80053-4. J Pediatr. 1997. PMID: 9329405 Review. No abstract available.
Cited by
-
Incidence and Risk Factors of Cholestasis in Newborns with Hemolytic Disease-A Case-Control Study.J Clin Med. 2024 May 29;13(11):3190. doi: 10.3390/jcm13113190. J Clin Med. 2024. PMID: 38892901 Free PMC article.
-
Hyperferritinaemia following intrauterine transfusions for Rh isoimmunisation.BMJ Case Rep. 2019 Feb 18;12(2):e227225. doi: 10.1136/bcr-2018-227225. BMJ Case Rep. 2019. PMID: 30782626 Free PMC article.
-
Conservative Management of Alloimmune Hemolysis and Cholestasis With Extreme Laboratory Abnormalities.Pediatrics. 2021 Feb;147(2):e20193367. doi: 10.1542/peds.2019-3367. Pediatrics. 2021. PMID: 33472986 Free PMC article.
-
Erythrokinetic mechanism(s) causing the "late anemia" of hemolytic disease of the fetus and newborn.J Perinatol. 2024 Jun;44(6):916-919. doi: 10.1038/s41372-024-01872-z. Epub 2024 Jan 12. J Perinatol. 2024. PMID: 38216678 Review.
-
Severe Cholestasis in Neonates with Hemolytic Disease of the Fetus and Newborn-A Case Report.J Clin Med. 2024 Feb 23;13(5):1272. doi: 10.3390/jcm13051272. J Clin Med. 2024. PMID: 38592131 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical